SELLAS Life Sciences Grou... (SLS)
NASDAQ: SLS
· Real-Time Price · USD
1.60
-0.03 (-1.84%)
At close: Jun 06, 2025, 3:59 PM
1.63
1.56%
After-hours: Jun 06, 2025, 05:57 PM EDT
-1.84% (1D)
| Bid | 1.61 |
| Market Cap | 160.14M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -27.13M |
| EPS (ttm) | -0.37 |
| PE Ratio (ttm) | -4.34 |
| Forward PE | -4.18 |
| Analyst | n/a |
| Ask | 1.63 |
| Volume | 2,381,413 |
| Avg. Volume (20D) | 1,878,984 |
| Open | 1.67 |
| Previous Close | 1.63 |
| Day's Range | 1.59 - 1.68 |
| 52-Week Range | 0.77 - 2.12 |
| Beta | 2.27 |
10 months ago
+4.59%
SELLAS Life Sciences Group shares are trading high...
Unlock content with
Pro Subscription
11 months ago
-0.82%
SELLAS Life Sciences shares are trading higher after the company was granted FDA Rare Pediatric Disease Designation for its SLS009 CDK9 inhibitor for the treatment of pediatric acute lymphoblastic leukemia, making it eligible for a priority review voucher worth over $100 million upon approval.
2 months ago · seekingalpha.com
Sellas Life Sciences: A Hold For Now With Huge, But Uncertain, Near-Term CatalystSellas Life Sciences Group, Inc.'s stock has dropped significantly, with a Hold rating due to uncertainty around the final Phase 3 trial data for GPS in AML. Interim results for GPS are promising but ...